L. Michael Glode, MD, FACP, FASCO, discusses the mechanism of action of PARP, the basic science behind Synthetic Lethal mutations, clinical trials for PARP inhibition in prostate cancer, and the importance of testing for DNA repair mutations.Read More
L. Michael Glodé, MD, FACP
[types usermeta='affiliation' user_is_author='true'][/types]
[types usermeta='location' user_is_author='true'][/types]
Dr. Glodé was the first board-certified Medical Oncologist at the University of Colorado, joining the faculty after training at Dana-Farber Cancer Institute. Dr. Glodé's research has been clinically focused on prostate cancer for many years. He headed the initial research on leuprolide, leading to it’s approval and subsequently developed a “single shot” castration agent that is in animal trials. He has also led efforts to evaluate a natural product, silibinin as a preventive or therapeutic agent and has been an investigator on more than 30 clinical trials, including the PI position for the largest adjuvant trial in prostate cancer, SWOG 9921. He has received numerous teaching awards and founded the AACR course “Molecular Biology for Clinical Oncologists” as well as serving as Founding Editor of the ASCO website, www.asco.org.